Helicobacter pylori infection
Conditions
Interventions
Group A:Berberine hydrochloride tablets 200mg + Vonoprazan fumarate tablets 20mg + amoxicillin capsule 1g, berberine hydrochloride tablets 3 times a day and all the rest of the medicines were given tw
Group B:Berberine hydrochloride tablets 300mg + Vonoprazan fumarate tablets 20mg + amoxicillin capsule 1g, berberine hydrochloride tablets 3 times a day, and all the rest of the medicines were given t
Group C:Colloidal bismuth pectin capsules 200mg + Rabeprazole sodium enteric-coated tablets 20mg + amoxicillin capsules 1g + clarithromycin tablets 0.5g, all medications were given twice a day for 14
Sponsors
Qianxinan People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Patients with a positive 13C/14C urea breath test and gastroscopy; with gastrointestinal symptoms such as epigastric pain, bloating, nausea, heartburn, acid reflux, and belching; no history of psychiatric disorders, and no communication barriers with the investigator; between 18 and 70 years of age; and willingness to be eradicated and signing of an informed consent form.
Exclusion criteria
Exclusion criteria: Hypersensitivity to the study drug; severe cardiac, pulmonary, hepatic, or renal disease;Prior treatment with antibiotics, acid suppressants, or bismuth within 4 weeks; children, pregnant women, and nursing mothers; glucose-6-phosphate dehydrogenase deficiency; patients with incomplete information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter pylori eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptom relief rate;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactJun Guo
Qianxinan People's Hospital
Outcome results
None listed